Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 11/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Coumaranone SCHEMBL69412 | 0.91 | PKM (0.56) | PKMTSHRMAOBMAOAMAPT | |
| 3-Coumaranone SCHEMBL29420742 | 0.91 | PKM (0.56) | PKMTSHRMAOBMAOAMAPT | |
| Acetic Acid SCHEMBL8221392 | 0.89 | HSD17B10 (0.44) | PKMTSHRMAOBMAOAMAPT | |
| SCHEMBL28709151 | 0.83 | PKM (0.63) | PKMTSHRMAOBMAOAMAPT | |
| SCHEMBL28425814 | 0.80 | RAB9A (0.49) | PKMMAOBMAPTSMN1; SMN2KMT2A | |
| SCHEMBL28426296 | 0.80 | CYP19A1 (0.49) | MAOBMAPTATMSMN1; SMN2KMT2A | |
| SCHEMBL7380169 | 0.79 | MAOA (0.60) | PKMTSHRMAOBMAOAMAPT | |
| SCHEMBL31218602 | 0.79 | MAOA (0.60) | PKMTSHRMAOBMAOAMAPT | |
| 3-Coumaranone SCHEMBL31042958 | 0.75 | MAOB (0.41) | PKMTSHRMAOBMAOAMAPT | |
| SCHEMBL10460744 | 0.75 | PKM (0.48) | PKMTSHRMAOBMAOAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108191887-B | Synthetic method of dibenzospiro [5,6] dodecanone derivative | 黑龙江大学 | 2020-07-28 | — | — | CN | claimed |
| EP-0041410-B1 | TRICYCLIC ETHERS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SCIENCE UNION ET Cie SOCIETE FRANCAISE DE RECHERCHE MEDICALE (FR) | 1983-11-09 | — | — | EP | claimed |
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | GENETIC INTELLIGENCE INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-11471323-B2 | Combination treatments | SCION NEUROSTIM, LLC (US) | 2022-10-18 | — | — | US | disclosed |
| CN-112111410-B | Preparation method of dibenzooxepinone compound | 扬州大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-112111410-B | Preparation method of dibenzooxepinone compound | 扬州大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-112111410-B | Preparation method of dibenzooxepinone compound | 扬州大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-112111410-A | Preparation method of dibenzoxepin compound | 扬州大学 | 2020-12-22 | — | — | CN | disclosed |
| CN-112111410-A | Preparation method of dibenzoxepin compound | 扬州大学 | 2020-12-22 | — | — | CN | disclosed |
| CN-108485987-B | Dibenzoxepin compound and preparation method and application thereof | 扬州大学 | 2020-10-09 | — | — | CN | disclosed |
| CN-108191887-B | Synthetic method of dibenzospiro [5,6] dodecanone derivative | 黑龙江大学 | 2020-07-28 | — | — | CN | disclosed |
| US-20090087571-A1 | LOW SHRINKAGE EPOXY-CATIONIC CURABLE COMPOSITION | HENKEL AG & CO., KGAA (DE) | 2009-04-02 | — | — | US | disclosed |
| EP-2021394-A1 | LOW SHRINKAGE EPOXY-CATIONIC CURABLE COMPOSITIONS | Henkel AG & Co. KGaA (DE) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007135094-A1 | LOW SHRINKAGE EPOXY-CATIONIC CURABLE COMPOSITIONS | HENKEL AG & CO. KGAA (DE) | 2007-11-29 | — | — | WO | disclosed |
| EP-0526402-B1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA GEIGY AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| US-4977158-A | Dibenzoxepinon and dibenzothiepino-pyridinol or - pyrrotol derivatives with anti-depressant action | AKZO N.V. (NL) | 1990-12-11 | — | — | US | disclosed |
| EP-0014053-B1 | SYNTHESIS OF VINDESINE; VINCALEUKOBLASTINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1983-12-14 | — | — | EP | disclosed |
| US-4089961-A | Antipsychotically useful quinolizidylidene derivatives of xanthenes, thioxanthenes and dibenzoxepins | SMITHKLINE CORPORATION (US) | 1978-05-16 | — | — | US | disclosed |
| US-4086350-A | FLUORO, CHLORO AND CYANO SUBSTITUTED 4-(9-XANTHENYLIDENE, 9-THIOXANTHENYLIDENE OR 11(6H)-DIBENZO(B,E)OXEPINYLIDENE)-1-METHYL-PIPERIDINES | SMITHKLINE CORPORATION (US) | 1978-04-25 | — | — | US | disclosed |
| US-4073912-A | Piperidylidene derivatives of benzo-fused xanthenes, thioxanthenes and dibenzoxepins and antipsychotic use thereof | SMITHKLINE CORPORATION (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | FNIP1, FN1, TNNC1 | PKM 3915/4885TSHR 3697/4885MAOB 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.